JPS56142213A - Pharmacuetical blend for treating parkinsonism syndrome - Google Patents
Pharmacuetical blend for treating parkinsonism syndromeInfo
- Publication number
- JPS56142213A JPS56142213A JP3265881A JP3265881A JPS56142213A JP S56142213 A JPS56142213 A JP S56142213A JP 3265881 A JP3265881 A JP 3265881A JP 3265881 A JP3265881 A JP 3265881A JP S56142213 A JPS56142213 A JP S56142213A
- Authority
- JP
- Japan
- Prior art keywords
- pharmacuetical
- blend
- treating parkinsonism
- parkinsonism syndrome
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803008993 DE3008993A1 (de) | 1980-03-08 | 1980-03-08 | Pharmazeutische zubereitungen |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS56142213A true JPS56142213A (en) | 1981-11-06 |
Family
ID=6096652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3265881A Pending JPS56142213A (en) | 1980-03-08 | 1981-03-09 | Pharmacuetical blend for treating parkinsonism syndrome |
Country Status (5)
Country | Link |
---|---|
US (1) | US4331687A (ja) |
EP (1) | EP0035597B1 (ja) |
JP (1) | JPS56142213A (ja) |
AT (1) | ATE8739T1 (ja) |
DE (2) | DE3008993A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08500093A (ja) * | 1992-06-23 | 1996-01-09 | セプラコア インコーポレーテッド | 光学的に純粋な(−)シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 |
CA2139000A1 (en) * | 1992-06-23 | 1994-01-06 | James W. Young | Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine |
US5961987A (en) * | 1996-10-31 | 1999-10-05 | University Of Iowa Research Foundation | Ocular protein stimulants |
JP2002503270A (ja) * | 1997-05-27 | 2002-01-29 | アクゾ・ノベル・エヌ・ベー | 体外血液回路における血餅形成を防止するためのオリゴ糖の使用 |
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
WO2002083631A1 (en) | 2001-04-13 | 2002-10-24 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
WO2018020366A1 (en) | 2016-07-26 | 2018-02-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Crystalline (r)-mandelate salt of (1r,2s)-2-phenylcyclopropylamine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2997422A (en) * | 1959-01-09 | 1961-08-22 | Smith Kline French Lab | Monoamine oxidase inhibition |
GB1438268A (en) | 1974-03-25 | 1976-06-03 | Nelson Research Dev Co | Antidepressant |
-
1980
- 1980-03-08 DE DE19803008993 patent/DE3008993A1/de not_active Withdrawn
- 1980-12-12 DE DE8080107848T patent/DE3068820D1/de not_active Expired
- 1980-12-12 EP EP80107848A patent/EP0035597B1/de not_active Expired
- 1980-12-12 AT AT80107848T patent/ATE8739T1/de not_active IP Right Cessation
-
1981
- 1981-03-03 US US06/240,161 patent/US4331687A/en not_active Expired - Lifetime
- 1981-03-09 JP JP3265881A patent/JPS56142213A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0035597A3 (en) | 1982-01-27 |
DE3068820D1 (en) | 1984-09-06 |
ATE8739T1 (de) | 1984-08-15 |
EP0035597B1 (de) | 1984-08-01 |
DE3008993A1 (de) | 1981-10-01 |
US4331687A (en) | 1982-05-25 |
EP0035597A2 (de) | 1981-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1555025A3 (en) | Use of dehydroepiandrosterone analogs for the treatment of asthma | |
HU9402771D0 (en) | Pharmaceutical compositions for wound healing and treatment of fibrotic disorders | |
DE3365465D1 (en) | Oral galenical forms of mopidamol | |
NZ303372A (en) | Use of (s)-oxybutynin and (s)-desethyloxybutynin to treat urinary incontinence | |
EP0147761A3 (en) | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer | |
JPS56142213A (en) | Pharmacuetical blend for treating parkinsonism syndrome | |
DE3683586D1 (de) | Behandlung des atemunwohlseinsyndroms bei erwachsenen. | |
PT97785A (pt) | Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina | |
ES482097A1 (es) | Procedimiento para preparar derivados acilicos de carnitina. | |
ES8507567A1 (es) | Metodo para estabilizar un concentrado de gamma globulina | |
ATE137965T1 (de) | Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege | |
DK0668077T3 (da) | Produkter, som indeholder G-CSF og TNF-bindende protein | |
RO117760B1 (ro) | Metodă pentru tratamentul unei afecţiuni de neurotransmisie serotoninergică defectivă | |
FR2533563B1 (ja) | ||
ATE44156T1 (de) | Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie. | |
EP0100516A3 (en) | 3-beta-(3'-(carboxypropionyloxy))-ursa-9(11),12-dience-28-carboxylic acid and its salts, process for its preparation and medicines containing these compounds | |
DE69525631D1 (de) | Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts | |
DE3275060D1 (en) | Use of beta-(1-adamantyl)-alpha, alpha-dimethylethylamine for the manufacture of a medicament for the treatment of otitis externa in dogs | |
YU44232B (en) | Process for obtaining alcalic salts of pyroxicame excreted onto pharmaceutical acceptable carrier | |
IL126795A (en) | Pharmaceutical compositions for the treatment of substance abuse disorders comprising pyridyl- and pyrimidyl-piperazines | |
EP0093497A3 (en) | Anthelmintic treatment | |
DE3470002D1 (en) | Use of l-fucose in the preparation of an inhalation composition and a process for preparing l-fucose | |
GB2019720A (en) | S-adenosyl-L-homocysteine and salts thereof for use in therapy | |
DE69736955D1 (de) | Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen | |
EP0182569A3 (en) | Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages |